Piper Sandler initiated coverage of Upstream Bio (UPB) with an Overweight rating and $75 price target The analyst believes Upstream’s verekitug has a differentiated mechanism of action that targets the TSLP receptor versus ligand. Accordingly, the TSLP ligand has been de-risked by Tezspire’s 2021 approval in severe asthma, which represents a rapidly growing biologic market opportunity of $7.5B, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UPB:
- Opening Day: Polyrizon, Gelteq debut in quiet IPO week
- Opening Day: Ingram Micro returns to trading in busy week
- Opening Day: Self-driving startup Pony.ai files for U.S. IPO
- Opening Day: Another trio of biotech IPOs make Friday debut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
